Oxford BioDynamics (LON:OBD) Stock Price Up 14.8% – Still a Buy?

Oxford BioDynamics Plc (LON:OBD) traded up 14.8% on Tuesday . The company traded as high as GBX 0.58 ($0.01) and last traded at GBX 0.56 ($0.01). 29,062,895 shares traded hands during mid-day trading, an increase of 6% from the average session volume of 27,511,123 shares. The stock had previously closed at GBX 0.49 ($0.01).

Oxford BioDynamics Price Performance

The firm has a market capitalization of £10.63 million, a P/E ratio of -0.10 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The business has a 50 day simple moving average of GBX 0.38 and a two-hundred day simple moving average of GBX 0.45.

Oxford BioDynamics (LON:OBD) last announced its earnings results on Monday, June 30th. The biotechnology company reported GBX (0.70) (($0.01)) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.